{"schema":"hottub-news/story/v1","story":"st_b4wvtkclozu3hzn3nmqq","title":"Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","title_en":null,"outlets":21,"brief":null,"page":"https://hottub.news/stories/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-b4wvtkcloz","count":63,"items":[{"id":"n_w6td3fhpknwnygogwxjq","seq":1448519,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.thewhig.com/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3","published":"2026-10-02T23:09:00Z","seen":"2026-10-02T23:36:20Z","lang":"en","source":{"id":"thewhig.com","name":"thewhig.com","domain":"thewhig.com","outlet":{"wikidata":"Q928635","name":"Kingston Whig-Standard","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_hanghina26incnckd2oq","seq":1460194,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.chathamdailynews.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T01:34:17Z","lang":"en","country":"CA","source":{"id":"chathamdailynews.ca","name":"chathamdailynews.ca","domain":"chathamdailynews.ca","outlet":{"wikidata":"Q126490070","name":"The Chatham Daily News","type":"newspaper","designations":["local newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_ripcswqxe4piiwj6ptpa","seq":1461591,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.recorder.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T01:51:09Z","lang":"en","country":"CA","source":{"id":"recorder.ca","name":"recorder.ca","domain":"recorder.ca"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_wfkfkaj3zfu2oen2jbua","seq":1466569,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.standard-freeholder.com/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T02:56:17Z","lang":"en","source":{"id":"standard-freeholder.com","name":"standard-freeholder.com","domain":"standard-freeholder.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_qydbypdyqn5oo22mqviq","seq":1466726,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.owensoundsuntimes.com/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T02:56:17Z","lang":"en","source":{"id":"owensoundsuntimes.com","name":"owensoundsuntimes.com","domain":"owensoundsuntimes.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_txtuhssh5hcpej5iuekq","seq":1468743,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.intelligencer.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T03:20:33Z","lang":"en","country":"CA","source":{"id":"intelligencer.ca","name":"intelligencer.ca","domain":"intelligencer.ca","outlet":{"wikidata":"Q4883859","name":"Belleville Intelligencer","type":"magazine","country":"CA","designations":["periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_nl2mywveedggactclksa","seq":1502536,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.theobserver.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T08:40:51Z","lang":"en","country":"CA","source":{"id":"theobserver.ca","name":"theobserver.ca","domain":"theobserver.ca","outlet":{"wikidata":"Q7424348","name":"Sarnia Observer","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_j2fgpykx3qt4v3lz6mfa","seq":1503072,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.elliotlakestandard.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T08:40:51Z","lang":"en","country":"CA","source":{"id":"elliotlakestandard.ca","name":"elliotlakestandard.ca","domain":"elliotlakestandard.ca"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_adqym2qls4q7ky4ookba","seq":1504953,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.simcoereformer.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T08:52:43Z","lang":"en","country":"CA","source":{"id":"simcoereformer.ca","name":"simcoereformer.ca","domain":"simcoereformer.ca","outlet":{"wikidata":"Q7764327","name":"The Simcoe Reformer","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_7ic3b3mrohaowcwgij2a","seq":1506993,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.stratfordbeaconherald.com/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T09:10:34Z","lang":"en","source":{"id":"stratfordbeaconherald.com","name":"stratfordbeaconherald.com","domain":"stratfordbeaconherald.com","outlet":{"wikidata":"Q7715988","name":"The Beacon Herald","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"entities":[{"id":"Q82059","name":"Nasdaq","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_2fhkpyzucy5szybqsxda","seq":1507852,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.nugget.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T09:22:12Z","lang":"en","country":"CA","source":{"id":"nugget.ca","name":"nugget.ca","domain":"nugget.ca","outlet":{"wikidata":"Q7054099","name":"North Bay Nugget","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_jgo53wwm4mayazwksepq","seq":1507914,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.thesudburystar.com/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T09:22:12Z","lang":"en","source":{"id":"thesudburystar.com","name":"thesudburystar.com","domain":"thesudburystar.com","outlet":{"wikidata":"Q7633528","name":"Sudbury Star","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_x44tqwmgjqmxup4ier4q","seq":1512082,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.northernnews.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T09:51:36Z","lang":"en","country":"CA","source":{"id":"northernnews.ca","name":"northernnews.ca","domain":"northernnews.ca","outlet":{"wikidata":"Q7058790","name":"Northern News","type":"newspaper","country":"CA","designations":["newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_unkbquufmc7sjg5o4lgq","seq":1528100,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.timminspress.com/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T12:06:49Z","lang":"en","source":{"id":"timminspress.com","name":"timminspress.com","domain":"timminspress.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_cpysonap2jhc2rpdf2pa","seq":1535452,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.saultstar.com/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T13:06:23Z","lang":"en","source":{"id":"saultstar.com","name":"saultstar.com","domain":"saultstar.com","outlet":{"wikidata":"Q7427395","name":"Sault Star","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_y437a7sbdovxmlnvjaja","seq":1535847,"kind":"article","title":"Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.brantfordexpositor.ca/press-releases/business-wire/alpha-cognition-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","published":"2026-10-02T23:09:00Z","seen":"2026-10-03T13:06:23Z","lang":"en","country":"CA","source":{"id":"brantfordexpositor.ca","name":"brantfordexpositor.ca","domain":"brantfordexpositor.ca","outlet":{"wikidata":"Q3643782","name":"Brantford Expositor","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"category2":"science-technology","sentiment":"neutral","tone":-0.07000000029802322,"political":0.03999999910593033},{"id":"n_7jbpd2yzu4etdp6llqzq","seq":1432319,"kind":"article","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/03/tmt-newswire/globenewswire/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2438259","published":"2026-10-02T20:50:00Z","seen":"2026-10-02T21:21:21Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7599999904632568,"sentiment":"neutral","tone":-0.14000000059604645,"political":0.09000000357627869},{"id":"n_pq7oglq26p272dxglndq","seq":1432382,"kind":"article","title":"ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/03/tmt-newswire/globenewswire/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2438260","published":"2026-10-02T20:50:00Z","seen":"2026-10-02T21:21:21Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6299999952316284,"sentiment":"neutral","tone":-0.05999999865889549,"political":0.05999999865889549},{"id":"n_ljdqru72eyda6egrk3jq","seq":1432655,"kind":"article","title":"Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/03/tmt-newswire/globenewswire/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2438256","published":"2026-10-02T20:50:00Z","seen":"2026-10-02T21:21:21Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7200000286102295,"sentiment":"neutral","tone":0.23999999463558197,"political":0.09000000357627869},{"id":"n_lwlsxtdzck72cicvid6q","seq":1432833,"kind":"article","title":"Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/03/tmt-newswire/globenewswire/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2438261","published":"2026-10-02T20:50:00Z","seen":"2026-10-02T21:21:21Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6600000262260437,"sentiment":"neutral","tone":-0.10000000149011612,"political":0.10999999940395355},{"id":"n_zmtxt7jaczhwcxvbjkfa","seq":1423410,"kind":"press_release","title":"Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374035/0/en/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock…","published":"2026-10-02T20:30:00Z","seen":"2026-10-02T20:38:19Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:xlo","us98422t1007"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7200000286102295,"sentiment":"neutral","tone":0.25,"political":0.09000000357627869},{"id":"n_zkqoh2ocu7wlmnz2646q","seq":1423413,"kind":"press_release","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374038/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees who began their employment with ORIC in September…","published":"2026-10-02T20:30:00Z","seen":"2026-10-02T20:38:19Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:oric","us68622p1093"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7599999904632568,"sentiment":"neutral","tone":0.25,"political":0.09000000357627869},{"id":"n_zzgetdsl7le23ha3zfaq","seq":1423414,"kind":"press_release","title":"ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374039/0/en/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements…","published":"2026-10-02T20:30:00Z","seen":"2026-10-02T20:38:19Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:ima","us45175g2075"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6299999952316284,"sentiment":"neutral","tone":0.30000001192092896,"political":0.05999999865889549},{"id":"n_xupyqbjbcnqor46cpz4q","seq":1423415,"kind":"press_release","title":"Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374040/0/en/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were…","published":"2026-10-02T20:30:00Z","seen":"2026-10-02T20:38:19Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:olma","us68062p1066"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6600000262260437,"sentiment":"neutral","tone":0.07999999821186066,"political":0.10999999940395355},{"id":"n_qnvdfp3nltqg3mcxoyja","seq":1422558,"kind":"press_release","title":"Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374015/0/en/apnimed-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on October 1, 2026, the compensation committee of Apnimed’s board of directors granted 19 new non-executive employees non-qualified stock options to…","published":"2026-10-02T20:05:00Z","seen":"2026-10-02T20:17:20Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:apmd","us03770y1073"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6899999976158142,"sentiment":"neutral","tone":0.17000000178813934,"political":0.09000000357627869},{"id":"n_g7ypp5hpzzjaoffh7awa","seq":1422560,"kind":"press_release","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374017/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","published":"2026-10-02T20:05:00Z","seen":"2026-10-02T20:17:20Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:vera","us92337r1014"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7400000095367432,"sentiment":"neutral","tone":0.23999999463558197,"political":0.07000000029802322},{"id":"n_6xlxn2e42xyjwjvay4cq","seq":1422568,"kind":"press_release","title":"PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374025/10002/en/petmeds-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.","published":"2026-10-02T20:05:00Z","seen":"2026-10-02T20:17:20Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:pets","us7163821066"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6899999976158142,"sentiment":"neutral","tone":0.3199999928474426,"political":0.07999999821186066},{"id":"n_u22e66pwxxgrtshldmyq","seq":1422569,"kind":"press_release","title":"Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374026/0/en/aardvark-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html","summary":"SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on October 1, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 60,000 shares of common stock.","published":"2026-10-02T20:05:00Z","seen":"2026-10-02T20:17:20Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:aard","us0029421007"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6899999976158142,"sentiment":"neutral","tone":0.3499999940395355,"political":0.05000000074505806},{"id":"n_v5hyy6mtkkyi2mut2r7q","seq":1422571,"kind":"press_release","title":"Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374028/0/en/spero-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero’s Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc.…","published":"2026-10-02T20:05:00Z","seen":"2026-10-02T20:17:20Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:spro","us84833t1034"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7400000095367432,"sentiment":"neutral","tone":0.27000001072883606,"political":0.07999999821186066},{"id":"n_ojdwcwbnrucxkvvxhrca","seq":1430627,"kind":"article","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.recorder.ca/press-releases/globe-newswire/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","published":"2026-10-02T20:03:00Z","seen":"2026-10-02T21:09:54Z","lang":"en","country":"CA","source":{"id":"recorder.ca","name":"recorder.ca","domain":"recorder.ca"},"via":"gdelt-gkg-english","topics":["economy","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q30253570","name":"Xenon Pharmaceuticals","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.07000000029802322,"political":0.10000000149011612},{"id":"n_7dqi42punld5jwzaxvaa","seq":1439423,"kind":"article","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.standard-freeholder.com/press-releases/globe-newswire/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","published":"2026-10-02T20:03:00Z","seen":"2026-10-02T22:17:26Z","lang":"en","source":{"id":"standard-freeholder.com","name":"standard-freeholder.com","domain":"standard-freeholder.com"},"via":"gdelt-gkg-english","topics":["economy","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q30253570","name":"Xenon Pharmaceuticals","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.07000000029802322,"political":0.10000000149011612},{"id":"n_dco7x7xei2nexj766vpa","seq":1443078,"kind":"article","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.owensoundsuntimes.com/press-releases/globe-newswire/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","published":"2026-10-02T20:03:00Z","seen":"2026-10-02T22:48:53Z","lang":"en","source":{"id":"owensoundsuntimes.com","name":"owensoundsuntimes.com","domain":"owensoundsuntimes.com"},"via":"gdelt-gkg-english","topics":["economy","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q30253570","name":"Xenon Pharmaceuticals","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.07000000029802322,"political":0.10000000149011612},{"id":"n_aheqzfr6do4gmkpt4elq","seq":1444337,"kind":"article","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.intelligencer.ca/press-releases/globe-newswire/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","published":"2026-10-02T20:03:00Z","seen":"2026-10-02T22:55:29Z","lang":"en","country":"CA","source":{"id":"intelligencer.ca","name":"intelligencer.ca","domain":"intelligencer.ca","outlet":{"wikidata":"Q4883859","name":"Belleville Intelligencer","type":"magazine","country":"CA","designations":["periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q30253570","name":"Xenon Pharmaceuticals","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.07000000029802322,"political":0.10000000149011612},{"id":"n_qnaiclxswpaal3faac7q","seq":1422257,"kind":"press_release","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374004/0/en/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of…","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:sndx","us87164f1057"],"entities":[{"id":"Q112085354","name":"Syndax Pharmaceuticals","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6299999952316284,"sentiment":"neutral","tone":0.1599999964237213,"political":0.11999999731779099},{"id":"n_55v5zqt3cd3vy2g5o2ha","seq":1422258,"kind":"press_release","title":"Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374005/0/en/inhibikase-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company’s common stock to two newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of September 30, 2026 (the “Effective Date”). The inducement grants were…","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:ikt","us45719w2052"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6399999856948853,"sentiment":"neutral","tone":0.17000000178813934,"political":0.10999999940395355},{"id":"n_qb7hvaypga2kqrhrvs2a","seq":1422259,"kind":"press_release","title":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374006/0/en/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation…","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:nams","nasdaq:namsw","nl00150012l7"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.20999999344348907,"political":0.07000000029802322},{"id":"n_osjvqiz7zahv5cfcpuza","seq":1422261,"kind":"press_release","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374008/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on October 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:ntla","us45826j1051"],"entities":[{"id":"Q54621387","name":"Intellia Therapeutics","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"sentiment":"neutral","tone":0.14000000059604645,"political":0.09000000357627869},{"id":"n_l745jgq52conaqjwvlqa","seq":1422262,"kind":"press_release","title":"Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374009/0/en/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:glue","us61225m1027"],"entities":[{"id":"Q3403","name":"Dufourspitze","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.800000011920929,"sentiment":"neutral","tone":0.2800000011920929,"political":0.07000000029802322},{"id":"n_ceug3zbmfchrbakuzfna","seq":1422263,"kind":"press_release","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374010/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share…","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:xene","ca98420n1050"],"entities":[{"id":"Q30253570","name":"Xenon Pharmaceuticals","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.18000000715255737,"political":0.10000000149011612},{"id":"n_az6ifaxrklbeli3f53xa","seq":1422265,"kind":"press_release","title":"Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374012/0/en/carlsmed-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material…","published":"2026-10-02T20:01:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:carl","us14280c1053"],"entities":[{"id":"Q139905539","name":"Carlsmed, Inc.","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7799999713897705,"sentiment":"neutral","tone":0.1899999976158142,"political":0.11999999731779099},{"id":"n_pfhhng6ibyzcz3ymynaq","seq":1422266,"kind":"press_release","title":"Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3374002/0/en/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units (RSUs) of Arcutis common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis…","published":"2026-10-02T20:00:00Z","seen":"2026-10-02T20:05:10Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:arqt","us03969k1088"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6499999761581421,"sentiment":"neutral","tone":0.28999999165534973,"political":0.07999999821186066},{"id":"n_ri566vv4ys4scmnpdeua","seq":1341252,"kind":"article","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2437980","published":"2026-10-02T12:04:00Z","seen":"2026-10-02T12:29:03Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.5299999713897705,"political":0.07999999821186066},{"id":"n_p7szoryjexbwkdxwr3sa","seq":1341736,"kind":"article","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635c4/2437977","published":"2026-10-02T12:04:00Z","seen":"2026-10-02T12:29:03Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["health","economy","business"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"positive","tone":-0.11999999731779099,"political":0.10000000149011612},{"id":"n_lnrviqmts745vghvbeza","seq":1335461,"kind":"press_release","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3373768/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html","summary":"DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the…","published":"2026-10-02T12:00:00Z","seen":"2026-10-02T12:03:00Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:tsha","us8776191061"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"positive","tone":0.4000000059604645,"political":0.10000000149011612},{"id":"n_u3m646nn7mxvw5s3g5ja","seq":1335470,"kind":"press_release","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3373761/0/en/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’…","published":"2026-10-02T11:59:00Z","seen":"2026-10-02T12:03:00Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:dmra","kyg2646y1044"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.23999999463558197,"political":0.07999999821186066},{"id":"n_zmp27llcp53ieg4xngvq","seq":1334325,"kind":"article","title":"Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2437962","published":"2026-10-02T11:44:00Z","seen":"2026-10-02T11:53:15Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"entities":[{"id":"Q30269121","name":"Kura Oncology","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":-0.019999999552965164,"political":0.12999999523162842},{"id":"n_lhqq3pvqzzj2qef5rc7q","seq":1334609,"kind":"article","title":"Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4/2437963","published":"2026-10-02T11:44:00Z","seen":"2026-10-02T11:53:15Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q107400383","name":"Abeona Therapeutics","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7599999904632568,"sentiment":"neutral","tone":0.25999999046325684,"political":0.05000000074505806},{"id":"n_nngyjlee76mg6pur2nnq","seq":1329460,"kind":"press_release","title":"Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3373755/35186/en/kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s…","published":"2026-10-02T11:30:00Z","seen":"2026-10-02T11:33:18Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:kura","us50127t1097"],"entities":[{"id":"Q30269121","name":"Kura Oncology","type":"org"}],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.17000000178813934,"political":0.11999999731779099},{"id":"n_4xhkou6lpunf3eiq4pba","seq":1329461,"kind":"press_release","title":"Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/02/3373756/0/en/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).","published":"2026-10-02T11:30:00Z","seen":"2026-10-02T11:33:18Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:abeo","us00289y1073"],"entities":[{"id":"Q107400383","name":"Abeona Therapeutics","type":"org"}],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7599999904632568,"sentiment":"neutral","tone":0.28999999165534973,"political":0.05000000074505806},{"id":"n_csd2lvisclfp4djb456q","seq":1352853,"kind":"article","title":"Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.daily-tribune.com/online_features/press_releases/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_5c2926f6-2233-5727-a859-10f5133cbbe7.html","published":"2026-10-02T11:30:00Z","seen":"2026-10-02T13:29:17Z","lang":"en","source":{"id":"daily-tribune.com","name":"daily-tribune.com","domain":"daily-tribune.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q107400383","name":"Abeona Therapeutics","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7599999904632568,"sentiment":"neutral","tone":0.23999999463558197,"political":0.05000000074505806},{"id":"n_b7zsgxywqu5fnsjh7e5a","seq":1220130,"kind":"press_release","title":"Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/01/3373446/0/en/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s…","published":"2026-10-01T21:10:00Z","seen":"2026-10-01T21:23:22Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:zntl","us98943l1070"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7699999809265137,"sentiment":"neutral","tone":0.27000001072883606,"political":0.10999999940395355},{"id":"n_npetfuukgn3o2m77s4za","seq":1218101,"kind":"press_release","title":"Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/01/3373432/0/en/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material…","published":"2026-10-01T21:00:00Z","seen":"2026-10-01T21:05:27Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:dnth","us2528281080"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.5699999928474426,"sentiment":"neutral","tone":0.25999999046325684,"political":0.09000000357627869},{"id":"n_xa5nuaolf76gxd46uaja","seq":1217498,"kind":"article","title":"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/2437635","published":"2026-10-01T20:38:00Z","seen":"2026-10-01T20:57:14Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.75,"sentiment":"neutral","tone":0.18000000715255737,"political":0.07000000029802322},{"id":"n_tqufvewzjzlrozqt7nfq","seq":1211605,"kind":"article","title":"Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"http://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302894983.html","published":"2026-10-01T20:30:00Z","seen":"2026-10-01T20:30:48Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","science","business"],"authors":["Karyopharm Therapeutics Inc."],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6600000262260437,"sentiment":"positive","tone":0.33000001311302185,"political":0.10000000149011612},{"id":"n_mzb2p2coa7zbrt27bnea","seq":1213194,"kind":"press_release","title":"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/01/3373419/0/en/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not…","published":"2026-10-01T20:30:00Z","seen":"2026-10-01T20:33:17Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:xfor","us98420x2027"],"entities":[{"id":"Q82059","name":"Nasdaq","type":"org"}],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.75,"sentiment":"neutral","tone":0.3199999928474426,"political":0.07000000029802322},{"id":"n_rgxgoebtii6hksexii5a","seq":1216764,"kind":"article","title":"Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2437593","published":"2026-10-01T20:18:00Z","seen":"2026-10-01T20:57:14Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","science","business","health"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.5600000023841858,"category2":"science-technology","sentiment":"neutral","tone":0.25,"political":0.05000000074505806},{"id":"n_narvcd5k6mkaobr65ava","seq":1217206,"kind":"article","title":"Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2437603","published":"2026-10-01T20:18:00Z","seen":"2026-10-01T20:57:14Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6700000166893005,"sentiment":"neutral","tone":0.25999999046325684,"political":0.10999999940395355},{"id":"n_vnabvqt7zqocmvkrlxnq","seq":1209860,"kind":"press_release","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/01/3373373/0/en/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s…","published":"2026-10-01T20:05:00Z","seen":"2026-10-01T20:16:11Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"}],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6399999856948853,"sentiment":"neutral","tone":0.20000000298023224,"political":0.09000000357627869},{"id":"n_3va34tczk5gyvxiqh4pa","seq":1209863,"kind":"press_release","title":"Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/01/3373376/0/en/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee.","published":"2026-10-01T20:05:00Z","seen":"2026-10-01T20:16:11Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:sldb","us83422e1055"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.5600000023841858,"category2":"science-technology","sentiment":"neutral","tone":0.3400000035762787,"political":0.05000000074505806},{"id":"n_hmlvhmxgqi2ah77vkiqa","seq":1209873,"kind":"press_release","title":"Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/10/01/3373387/37519/en/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","summary":"WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with…","published":"2026-10-01T20:05:00Z","seen":"2026-10-01T20:16:11Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:akba","us00972d1054"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.6700000166893005,"sentiment":"neutral","tone":0.17000000178813934,"political":0.10999999940395355},{"id":"n_5yzkhoxkxpnkt6sdle6q","seq":1009582,"kind":"article","title":"Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.manilatimes.net/2026/10/01/tmt-newswire/globenewswire/adial-pharmaceuticals-announces-inducement-grant-under-nasdaq-listing-rule-5635c4/2436655","published":"2026-09-30T21:53:00Z","seen":"2026-09-30T22:13:35Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","politics","business","health"],"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7799999713897705,"sentiment":"positive","tone":0.10000000149011612,"political":0.05000000074505806},{"id":"n_gfq4l337himiq7wuryia","seq":1006699,"kind":"press_release","title":"Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/09/30/3372449/0/en/adial-pharmaceuticals-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html","summary":"GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company.","published":"2026-09-30T21:46:00Z","seen":"2026-09-30T21:54:11Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:adil","us00688a3041"],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.7799999713897705,"sentiment":"positive","tone":0.3499999940395355,"political":0.05000000074505806},{"id":"n_b4wvtkclozu3hzn3nmqq","seq":760130,"kind":"press_release","title":"Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://www.globenewswire.com/news-release/2026/09/29/3371315/0/en/arvinas-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html","summary":"NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of…","published":"2026-09-29T20:01:00Z","seen":"2026-09-29T20:16:43Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:arvn","us04335a1051"],"entities":[{"id":"Q82059","name":"Nasdaq","type":"org"}],"mentions":2,"story":"st_b4wvtkclozu3hzn3nmqq","category":"economy-business","category_p":0.8799999952316284,"sentiment":"neutral","tone":0.2800000011920929,"political":0.05999999865889549}]}